Table 2.
Baseline cognitive and psychological measures of the study population comparing patients with non-dialysis CKD and ESKD
| Overall population (n=223) Median (IQR)/% |
Patients with CKD (n=114) Median (IQR)/% |
Patients with ESKD (n=109) Median (IQR)/% |
P value* | |
| Modified Mini-Mental State Examination (3MS) score† | 94 (890–97) | 95 (91–97) | 93 (86–96) | 0.001 |
| Cognitive impairment (patients with 3MS score <85%) | 17.6% | 12.3% | 23.2% | 0.033 |
| Trail-making test A (TMT-A) (s) | 38 (29–52.5) | 35 (28–45) | 43.5 (33–68) | <0.001 |
| Trail-making test B (TMT-B) (s) | 100 (73–143) | 82 (65–117) | 120 (83–201) | <0.001 |
| Difference between TMT-A and TMT-B (s) | 62 (40–94) | 46 (33–76) | 72 (49–129) | <0.001 |
| Stroop interference score | −2.5 (−7.2 to 2.8) | −1.6 (−6.1 to 3.9) | −3.6 (−8.2 to 1.4) | 0.055 |
| Beck Depression Inventory 2 (BDI-2) score | 9 (4–14) | 6.5 (3–11) | 10 (5–17) | <0.001 |
| Depression (based on BDI-2 score of 14 or above) | 26.9% | 14.9% | 39.5% | <0.001 |
p values with a significance level <0.05 are shown in bold format.
*P value for difference estimated by Wilcoxon rank-sum test for continuous variables and χ2 test for difference in proportions.
†Median and IQR.
CKD, chronic kidney disease; ESKD, end-stage kidney disease.